Varadhachary, Gauri

Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018

Loree, J. M., Anand, S., Dasari, A., Unger, J. M., Gothwal, A., Ellis, L. M., Varadhachary, G., Kopetz, S., Overman, M. J., & Raghav, K. (2019) · JAMA Oncology

Ethics in Clinical ResearchRace, Genetics, and Society

Cited by 570

Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies

Javle, M. M., Shroff, R. T., Xiong, H., Varadhachary, G. A., Fogelman, D., Reddy, S. A., Davis, D., Zhang, Y., Wolff, R. A., & Abbruzzese, J. L. (2010) · BMC Cancer

PI3K/AKT/mTOR signaling in cancerPancreatic and Hepatic Oncology Research

Cited by 170

Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA Variants: Findings From 2 Phase 2 Nonrandomized Clinical Trials

Javle, M., Shacham-Shmueli, E., Xiao, L., Varadhachary, G., Halpern, N., Fogelman, D., Boursi, B., Uruba, S., Margalit, O., Wolff, R. A., et al. (2021) · JAMA Oncology

PARP inhibition in cancer therapyPancreatic and Hepatic Oncology Research

Cited by 127